ASND
Ascendis Pharma A/S
September 15, 2026 · market open
- Rarity
- 3.49
- Peak move
- −13.53%
- Float cap
- $16.1B
Ascendis Pharma A/S is a biopharmaceutical company using its TransCon technology platform to develop and commercialize therapies for endocrine rare diseases and oncology. The company markets YORVIPATH for hypoparathyroidism and SKYTROFA for growth hormone deficiency, primarily to patients in the U.S. and Europe. It also has a pipeline including TransCon CNP for achondroplasia and oncology candidates.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
6 events · 0 from SEC or newswire · 0 timed with the moveanalyst_ratingRaymond James downgraded Ascendis Pharma to Outperform from Strong Buy while maintaining a $287 price target, following the company's announcement that it will regain TransCon metabolic and cardiovascular rights from Novo Nordisk and its $400 million buyback.
- Key event
executive_remarkAt the Morgan Stanley 24th Annual Global Healthcare Conference on Sept. 15, 2026, Ascendis CEO Jan Mikkelsen and CFO Scott Smith discussed the $400 million buyback, regaining the metabolic/cardiovascular franchise from Novo Nordisk, and Vision 2030 targets including EUR 5 billion in product revenue and over EUR 500 million of 2026 operating cash flow, and said the company will not raise equity capital.
- Key event
buybackAscendis Pharma's Board of Directors authorized a share repurchase program of up to $400 million of its ordinary shares, announced Sept. 14, 2026, to be executed via open market purchases, privately negotiated transactions, block trades, accelerated share repurchase transactions or 10b5-1 plans.
- Key event
reg_fd_disclosureAscendis Pharma will regain exclusive rights to develop, manufacture and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon semaglutide for obesity and type 2 diabetes, after terminating its Novo Nordisk collaboration announced in November 2024, with neither party having continuing financial obligations.
analyst_ratingH.C. Wainwright analyst M. Kapoor raised the FY2026 EPS estimate for Ascendis Pharma to $3.93 from $3.85, above the $3.69 consensus, and forecast FY2027 EPS of $11.30, in a Sept. 10, 2026 note.
analyst_ratingTD Cowen reiterated a Buy rating and $341 price target on Ascendis Pharma following encouraging Week 52 infant data from the Phase 2 reACHin study of Yuviwel in achondroplasia.